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Non Hodgkin T cell lymphoma: an atypical clinical 
presentation *







Abstract: Cytotoxic lymphomas comprise a spectrum of peripheral T-cell lymphomas that can have a initial or
late cutaneous presentation. We describe a 46-year-old man from Cape Verde, with a dermatosis involving his
face and trunk, consisting of monomorphic papules with a smooth surface and both motor and sensory polyneu-
ropathy.The hypothesis of leprosy was supported by the clinical and initial hystopathological findings and the
patient was referred to our hospital with suspected Hansen’s disease. In the new skin and lymph node biopsies
a lymphocyte population was identified whose immunohystochemistry study allowed the diagnosis of T-cell
lymphoma with expression of cytotoxic markers. The patient was started on chemotherapy with initial remission
of the skin lesions but, subsequently, progression of systemic disease.
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Resumo: Os linfomas citotóxicos compreendem um espectro de linfomas de células T periféricos e linfomas
Natural Killer que podem ter expressão cutânea primária ou secundária. Descrevemos o caso de um homem com
46 anos de idade, natural de Cabo Verde,com dermatose envolvendo a face e tronco constituída por pápulas
monomorfas superfície lisa e polineuropatia sensitivo motora.A hipótese de Hanseníase foi colocada suportada
por achados histopatológicos sugestivos sendo o doente referenciado à consulta de Doença de Hansen do nosso
hospital. Em biopsia de pele e de gânglio identificou-se proliferação linfocitária cujo estudo imunohistoquímico
permitiu o diagnóstico de linfoma T com expressão de marcadores citotóxicos. Iniciou quimioterapia verifican-
do-se inicialmente remissão parcial das lesões cutâneas mas posteriormente a progressão da doença sistémica. 
Palavras-chave: Citotoxicidade imunológica; Hanseníase; Linfoma cutâneo de células T; Polineuropatia paraneo-
plásica
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INTRODUCTION
Cytotoxic cutaneous lymphomas are a group of
lymphoproliferative disorders characterized by
expression of cytotoxic proteins (TIA-1, granzyme A
or B or perforin). 1,2 The diagnosis of these conditions
can sometimes be clinically and histopathologically
challenging.
CASE REPORT
We describe a 46-year-old, black male patient,
born in Cape Verde. He first noted, months prior to
presentation, a dermatosis that almost exclusively
involved his face and trunk consisting of multiple
small monomorphic papules with an erythematous
smooth surface. 1,2 The patient reported dysesthesia at
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the distal ends of both feet and paroxistical difficulty
in mobilizing both feet. These symptoms suggested
the existence of a sensory motor polyneuropathy.A
cutaneous biopsy was performed motivated by these
findings. The histopathological evaluation revealed
perivascular and periadnexal inflammatory infiltra-
tion of nerve bundles with lymphocytic permeation
which, with simultaneous findings of cutaneous
involvement and sensory motor polyneuropathy,
could be consistent with the diagnosis of leprosy. The
patient was therefore referred for a consultation at the
hospital regarding the possibility of Hansen’s disease.
The physical examination revealed a dermatosis
involving the face and the upper torso that consisted
of multiple infracentimetric monomorphic papules
and plaques with a smooth erythematous surface
(Figures 1 and 2). There was no hypoesthesia in rela-
tion to skin lesions. Examination of ganglionic chains
revealed several adenopathies below the chin and in
axillary chains. The adenopathies that were found
were over one centimeter in diameter, with a hard
consistency. Palpation of the abdomen revealed no
masses or organomegaly. 
The neurological examination did not reveal
thickening or pain upon palpation of the nerve roots.
There was slight hypoesthesia at the distal end of both
feet, with diminished thermal, tactile and pain sensi-
tivity.
The patient also reported weight loss of 12
kg(>10%) during the past year which had never been
taken into consideration. The patient denied any
other constitutional symptoms, including fever,
anorexia and malaise.
The supplementary study revealed: normocytic
normochromic anemia(10.4 g/dL), white blood cell
count with lymphocytosis(3500) and thrombocytope-
nia (94000),VS 71mm in 1st hour, β2-microglobulin(8.0
mg/dL) and LDH(689 U/L) and negative results for
HIV, HTLV, EBV.
PCR applied to a biopsy performed from the
synovial tissue proved negative for M. leprae.
Body axial tomography showed severe gan-
glion involvement of the axillary and inguinal lymph
nodes and mild splenomegaly with multiple small
parenchymal nodules.
The skin biopsy revealed diffuse lymphoid infiltra-
tion in the dermis composed of CD3, CD4 positive T-
cells, some of which had CD8 positivity (Figures 3, 4
and 5). The axillary lymph node biopsy identified a
lymphocytic proliferation composed of small cells
with CD2, CD3 positive cells and CD7, CD8, CD20
negative cells, and TIA expression allowing the diag-
nosis of T-cell lymphoma with cytotoxic expression
(Figure 6). The study of T-cell receptors rearrange-















FIGURE 3: Hystopatology (H&E). Dermal intense and difuse 
infiltration of lymph cells
Non Hodgkin T cell lymphoma: an atypical clinical presentation 265
An Bras Dermatol. 2013;88(2):264-7.
population based on the analysis of gamma genes.The
absence of typical clinical lesions and the typical his-
tological markers of Hansen’s disease, the successive-
ly negative nasal smears and skin swabs, together
with the PCR detection technique for M. leprae,
allowed for the exclusion of a Hansen’s disease diag-
nosis. The evaluation by a neurologist allowed a cor-
relation between lymphoma and demyelinating neu-
ropathy to be characterized as a rare paraneoplastic
syndrome.
The patient was started on chemotherapy with
CHOP (cyclophosphamide, doxorubicin, vincristine
and prednisolone), which led to partial remission of
the cutaneous lesions (Figure 6) but with subsequent
loss of response. Second line therapeutic management
with ESHAP (etoposide, methylprednisolone, cytara-
bine and cisplatin ) was then initiated with no notice-
able clinical response. The patient was then started on
a CMOPP chemotherapy regimen (cyclophos-
phamide, mechlorethamine, vincristine, procarbazine
and prednisolone), but at 12 months follow-up there
was invariable progression of the systemic disease,
resulting in the patient´s death.
DISCUSSION
The heterogeneous cutaneous clinical presenta-
tion of T-cell lymphomas, together with the frequent
occurrence of nonspecific histological findings in cuta-
neous biopsies, creates significant diagnostic difficul-
ties. The cutaneous lymphoma classification is also a
challenge, in addition to the problem that until a few
years ago there was no consensus between the WHO
and the EORTC (European Organization for Research
and Treatment of Cancer). 1,3 The new classification
allows for more uniformity regarding both the diag-
nosis and therapeutic approach to these lymphomas.4
In the case of our patient, there was already sys-
temic involvement at the date of diagnosis, and in
these circumstances this lymphoma could not be clas-
sified as primary cutaneous T-cell lymphoma. These
lymphomas are characterized by a transient partial
response to chemotherapy and by its association with
a poor prognosis. The demyelinating neuropathy has
been otherwise described since lymphomas have been
reported to occasionally involve the peripheral nerv-
ous system. This damage is more often caused by non-
Hodgkin T-cell lymphomas, the cells of which can
infiltrate the nerve sheath and cause axonal damage,
or by an autoimmune process where antineuronal anti-
bodies are directed against intracellular antigens. 5,6
Furthermore our patient’s lymphoma exhibited
cytotoxic behavior characterized by the expression of
molecules such as TIA, perforin and granzyme B. The
expression of these molecules is of great diagnostic
use and helps the dermatologist to classify lym-
FIGURE 5: Immunochemistry (CD4).  Lymph cells infiltrate 
showing CD4 positivity
FIGURE 4: Immunochemistry study (CD3).  Lymph cell infiltrate
showing CD3 positivity
FIGURE 6: Immunochemistry study (TiA). The immunochemistry
study showing a difuse infiltrate of lymph cells with cytotoxic
expression  (TiA+)
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phoma; however, the use of these markers lacks clini-
cal and phenotypic specificity. 7 The surface markers
expressed in malignant T-cells: CD2, CD3, CD4, CD25
and CD52 were the first therapeutic targets to be iden-
tified. However, the presence of these receptors, even
in normal T-cells, implies that therapy with mono-
clonal antibodies or immunotoxins inevitably results
in different degrees of immunosuppression. New
classes of therapeutic agents have emerged, particu-
larly those that act by inhibiting histone deacety-
lase(HDAC).8,9 These molecules are intended to
induce apoptosis in malignant T-cells. Immuno -
modulators such as interferon and toll-like receptor
agonists (TLR), also have a particularly important role
in the treatment of primary cutaneous lymphomas
(CTCL).9 While most classical cytotoxic drugs have
limited effectiveness in the treatment of lymphomas,
agents that inhibit the metabolism of purine and
pyrimidine (nucleoside analogues) seem to have some
additional efficacy in cases of T-cell lymphoma.9,10
Clinical trials currently underway will better define
therapeutic strategies for these lymphomas.
We stress the importance of this case due to the
uncommon clinical presentation, in particular the
simultaneous neurological and skin involvement that
required a thorough investigation of multiple differ-
ential diagnoses. This may ultimately result in a later
diagnosis of Non-Hodgkin’s peripheral T-cytotoxic
lymphoma.  ❑
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